Profluent's Ali Madani on taking biology from discovery to design: the $2.25B Eli Lilly deal, sequence vs. structure, and the "GPT-1.5 era" of biology.
From discovery to design: in conversation…
Profluent's Ali Madani on taking biology from discovery to design: the $2.25B Eli Lilly deal, sequence vs. structure, and the "GPT-1.5 era" of biology.